# Chia Tai Tianqing Pharmaceutical Group trials: 320 (2026)

ClinicalTrials.gov lists 320 trials with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor, 52 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: 320 rows for $16, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 320
- Recruiting or not yet: 52
- Read on: November 19, 2026

## Trials

The 25 newest of 320, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 1, 2026 | NCT07798284 | A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Overweight/Obesity | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798284) |
| September 1, 2026 | NCT07797231 | Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Chronic Hepatitis B | 930 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797231) |
| August 7, 2026 | NCT07753369 | A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753369) |
| August 5, 2026 | NCT07747857 | A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Type 2 Diabetes Mellitus Combined With Overweight or Obesity | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747857) |
| July 31, 2026 | NCT07738679 | Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Advanced Solid Tumors | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738679) |
| July 16, 2026 | NCT07708272 | QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Active not recruiting | Myelofibrosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708272) |
| July 13, 2026 | NCT07697443 | Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697443) |
| June 23, 2026 | NCT07663526 | Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 4 | Recruiting | Crohn's Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663526) |
| June 23, 2026 | NCT07663331 | A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 4 | Recruiting | Adult Non-infectious Uveitis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663331) |
| June 8, 2026 | NCT07633314 | A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Suspended | Chronic Obstructive Pulmonary Disease | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633314) |
| May 27, 2026 | NCT07608666 | Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Active not recruiting | Myelofibrosis | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608666) |
| May 6, 2026 | NCT07569757 | Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Multiple Myeloma | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569757) |
| May 4, 2026 | NCT07564505 | A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 4 | Recruiting | Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564505) |
| April 24, 2026 | NCT07551427 | A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Myelofibrosis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551427) |
| April 23, 2026 | NCT07548177 | Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Alveolar Soft Part Sarcoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548177) |
| April 20, 2026 | NCT07538973 | A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Not yet recruiting | Lung Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538973) |
| April 14, 2026 | NCT07529925 | A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 4 | Not yet recruiting | Severe Plaque Psoriasis in Chinese Children | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529925) |
| April 6, 2026 | NCT07512596 | Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512596) |
| April 3, 2026 | NCT07509892 | A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509892) |
| March 19, 2026 | NCT07482592 | Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Advanced Malignant Cancer | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07482592) |
| March 18, 2026 | NCT07480824 | To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Myelofibrosis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480824) |
| March 11, 2026 | NCT07464587 | Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464587) |
| February 12, 2026 | NCT07407803 | Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | Plexiform Neurofibroma | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407803) |
| January 26, 2026 | NCT07367529 | A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Advanced Lung Cancer | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07367529) |
| January 26, 2026 | NCT07367516 | Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Esophageal Cancer | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07367516) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 120 |
| Phase 1/2 | 42 |
| Phase 2 | 79 |
| Phase 2/3 | 8 |
| Phase 3 | 54 |
| Phase 4 | 7 |
| Not applicable | 7 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 156 |
| Completed | 69 |
| Recruiting | 39 |
| Terminated | 26 |
| Active not recruiting | 13 |
| Not yet recruiting | 13 |
| Withdrawn | 3 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 16 |
| Pulmonary Disease, Chronic Obstructive | 14 |
| Hepatitis B, Chronic | 12 |
| Breast Neoplasms | 11 |
| Primary Myelofibrosis | 10 |
| Neoplasms | 8 |
| Hematologic Neoplasms | 5 |
| Diabetes Mellitus, Type 2 | 5 |
| Colorectal Neoplasms | 5 |
| Recurrence | 5 |
| Leukemia, Myeloid, Acute | 4 |
| Myelodysplastic Syndromes | 4 |
| Uterine Cervical Neoplasms | 4 |
| Hemophilia A | 4 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Lung Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Carcinoma, Hepatocellular | 3 |
| Multiple Myeloma | 3 |
| Asthma | 3 |
| Obesity | 3 |
| Lupus Erythematosus, Systemic | 3 |
| Sarcoma | 3 |
| Stomach Neoplasms | 3 |
| Nasopharyngeal Carcinoma | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Public relations firms in the United States](https://specstream.ai/data/businesses/public-relations-firms/united-states)
- [Escrow companies in the United States](https://specstream.ai/data/businesses/escrow-companies/united-states)
- [Trucking companies in the United States](https://specstream.ai/data/businesses/trucking-companies/united-states)
- [Inventory control companies in the United States](https://specstream.ai/data/businesses/inventory-control-companies/united-states)
- [B2B secretarial companies in the United States](https://specstream.ai/data/businesses/b2b-secretarial-companies/united-states)
